US5393739A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1993-09-15
•
Granted: 1995-02-28
•
Expires: 2013-09-15
Abstract
Abstract Bone morphogenetic proteins -2 and -3 (BMPs -2 and -3) work in synergistic combination with TGF-βz to provide compositions with increased osteogenic activity. Methods of treating bone defects, inducing bone growth and increasing bone marrow cell production using these compositions are also disclosed.
Inventors
- 👤 Hanne Bentz
- 👤 Andrea Y. Thompson
- 👤 Rosa Armstrong
- 👤 David M. Rosen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 23:42
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/51; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K38/1875; A61P; A61P19/00; A61P43/00; C07K14/495
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
35 words
A composition for treating cartilage and/or bone defects consisting essentially of: bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-3 (BMP-3), transforming growth factor-β2 (TGF-β2) together in a tissue-growth-inducing amount; and a pharmaceutically acceptable carrier or excipient.
Claim 2
Dependent Claim
35 words
A composition for treating cartilage and/or bone defects consisting essentially of: bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-3 (BMP-3), transforming growth factor-β2 (TGF-β2) together in a tissue-growth-inducing amount; and a pharmaceutically acceptable carrier or excipient.
Claim 3
Dependent Claim
35 words
An osteogenic composition for inducing bone growth consisting essentially of: bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-3 (BMP-3), and transforming growth factor-β2 (TGF-β2) together in a bone-growth-inducing amount; and a pharmaceutically acceptable carrier or excipient.
Claim 4
Dependent Claim
35 words
An osteogenic composition for inducing bone growth consisting essentially of: bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-3 (BMP-3), and transforming growth factor-β2 (TGF-β2) together in a bone-growth-inducing amount; and a pharmaceutically acceptable carrier or excipient.
Claim 5
Independent Claim
52 words
A method for treating bone and cartilage formation in an individual having a cartilage or bone defect comprising: administering to the individual a composition consisting essentially of bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-3 (BMP-3) and transforming growth factor-β2 (TGF-β2) together in a tissue-growth-inducing amount, and a pharmaceutically acceptable carrier or excipient.
Claim 6
Independent Claim
52 words
A method for treating bone and cartilage formation in an individual having a cartilage or bone defect comprising: administering to the individual a composition consisting essentially of bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-3 (BMP-3) and transforming growth factor-β2 (TGF-β2) together in a tissue-growth-inducing amount, and a pharmaceutically acceptable carrier or excipient.
Claim 7
Independent Claim
49 words
A method for inducing bone marrow cell production in an individual comprising: administering to the individual a composition consisting essentially of bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-3 (BMP-3) and transforming growth factor-β2 (TGF-β2) together in a bone marrow cell growth-inducing amount, and a pharmaceutically acceptable carrier or excipient.
Claim 8
Independent Claim
49 words
A method for inducing bone marrow cell production in an individual comprising: administering to the individual a composition consisting essentially of bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-3 (BMP-3) and transforming growth factor-β2 (TGF-β2) together in a bone marrow cell growth-inducing amount, and a pharmaceutically acceptable carrier or excipient.
References Cited (Backward Citations)
US4789732A
Cited
US4294753A
Cited
US4455256A
Cited
US4434094A
Cited
US4795804A
Cited
US4563489A
Cited
US4608199A
Cited
US4774322A
Cited
US4886747A
Cited
US4806523A
Cited
US4877864A
Cited
WO1989009787A2
Cited
WO1989009788A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-02-27 | 1998-08-29 | 1999-02-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-02-27 | 2002-08-29 | 2003-02-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-02-27 | 2006-08-29 | 2007-02-28 | $7700.00 | Window Closed / Lapsed |